Praxis Bioresearch, LLC
Praxis Bioresearch is a privately held biopharmaceutical company focused on developing novel therapies for neurological conditions, specifically targeting ADHD and apathy in Alzheimer's Disease. Their mission is to translate biological insights into innovative therapies that address critical unmet medical needs, with a strategic focus on safety, efficacy, and patient-centric features. They aim to transform treatment paradigms in neurology and psychiatry through their innovative drug PRX-P4-003, which has potential applications in ADHD and Alzheimer's Disease, and is distinguished by its balanced mechanism, abuse deterrence, and extended duration of action.
Industries
Nr. of Employees
small (1-50)
Praxis Bioresearch, LLC
10940 Wilshire Blvd Ste 600, Los Angeles, CA 90024
Patents
Products
Oral prodrug small-molecule candidate for CNS indications (development-stage)
A development-stage oral prodrug designed for gut-specific activation to modulate central dopamine pathways, intended for indications including ADHD and apathy in Alzheimer's disease; advanced through IND clearance and early human PK evaluation.
Oral prodrug small-molecule candidate for CNS indications (development-stage)
A development-stage oral prodrug designed for gut-specific activation to modulate central dopamine pathways, intended for indications including ADHD and apathy in Alzheimer's disease; advanced through IND clearance and early human PK evaluation.
Services
End-to-end in-house services covering discovery, preclinical testing, CMC development, regulatory filing and initiation of early-phase human studies for CNS small molecules.
Strategic market assessment and partner outreach to enable collaborations, licensing or co-development in CNS therapeutic areas.
End-to-end in-house services covering discovery, preclinical testing, CMC development, regulatory filing and initiation of early-phase human studies for CNS small molecules.
Strategic market assessment and partner outreach to enable collaborations, licensing or co-development in CNS therapeutic areas.
Expertise Areas
- CNS drug development
- Prodrug design and enzymatic activation strategies
- Clinical pharmacology and early-phase trials
- CMC and GMP manufacturing for clinical supply
Key Technologies
- Prodrug design
- Enzyme-activated oral drug delivery (pancreatic lipase)
- Oral small-molecule pharmacokinetic optimization
- GMP API and finished-product development